mTOR signaling in cellular and organismal energetics

Current Opinion in Cell Biology

Volumn 33, Issue 1, 2015, Pages 55-66

  Albert, Verena ^a   Hall, Michael N ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NUCLEOTIDE; TARGET OF RAPAMYCIN KINASE;

ADIPOSE TISSUE; BROWN ADIPOSE TISSUE; CELL ENERGY; ENERGY METABOLISM; HUMAN; HYPOTHALAMUS; LIVER; LIVER CELL; MITOCHONDRION; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; HOMEOSTASIS; METABOLIC DISORDER; METABOLISM;

MAMMALIA;

ADIPOSE TISSUE; ANIMALS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; HYPOTHALAMUS; LIVER; METABOLIC DISEASES; MITOCHONDRIA; MUSCLE, SKELETAL; NUCLEOTIDES; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84930363624     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2014.12.001     Document Type: Review

References (91)

1. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124(3):471-484.
2. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149(2):274-293.
3. Loewith R., Hall M.N. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 2011, 189(4):1177-1201.
4. Shimobayashi M., Hall M.N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 2014, 15(3):155-162.
5. Dibble C.C., Manning B.D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 2013, 15(6):555-564.
6. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10(5):307-318.
7. Zinzalla V., et al. Activation of mTORC2 by association with the ribosome. Cell 2011, 144(5):757-768.
8. Cybulski N., Hall M.N. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci 2009, 34(12):620-627.
9. Sparks C.A., Guertin D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29(26):3733-3744.
10. Kim S.G., Buel G.R., Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells 2013, 35(6):463-473.
11. Mamane Y., et al. mTOR: translation initiation and cancer. Oncogene 2006, 25(48):6416-6422.
12. Chauvin C., et al. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 2014, 33(4):474-483.
13. Ruvinsky I., Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006, 31(6):342-348.
14. Raught B., et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 2004, 23(8):1761-1769.
15. Shahbazian D., et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 2006, 25(12):2781-2791.
16. Peschiaroli A., et al. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell 2006, 23(3):319-329.
17. Wang X., et al. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 2001, 20(16):4370-4379.
18. Wilson K.F., Wu W.J., Cerione R.A. Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex. J Biol Chem 2000, 275(48):37307-37310.
19. Richardson C.J., et al. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 2004, 14(17):1540-1549.
20. Ma X.M., et al. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 2008, 133(2):303-313.
21. Mieulet V., et al. S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am J Physiol Cell Physiol 2007, 293(2):C712-C722.
22. Hsieh A.C., et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485(7396):55-61.
23. Thoreen C.C., et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012, 485(7396):109-113.
24. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci Signal 2009, 2(67):ppe24.
25. Faller W.J., et al. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 2014, [Epub ahead of print].
26. Larsson O., et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A 2012, 109(23):8977-8982.
27. Morita M., et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 2013, 18(5):698-711.
28. Meyuhas O., Kahan T. The race to decipher the top secrets of TOP mRNAs. Biochim Biophys Acta 2014, [Epub ahead of print].
29. Zhang Y., et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 2014, 513(7518):440-443.
30. Betz C., et al. Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc Natl Acad Sci U S A 2013, 110(31):12526-12534.
31. Hsieh A.C., et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17(3):249-261.
32. Oh W.J., et al. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J 2010, 29(23):3939-3951.
33. Dai N., et al. mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes Dev 2013, 27(3):301-312.
34. Estaquier J., et al. The mitochondrial pathways of apoptosis. Adv Exp Med Biol 2012, 942:157-183.
35. Weinberg F., Chandel N.S. Mitochondrial metabolism and cancer. Ann N Y Acad Sci 2009, 1177:66-73.
36. Schieke S.M., et al. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006, 281(37):27643-27652.
37. Bentzinger C.F., et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 2008, 8(5):411-424.
38. Risson V., et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol 2009, 187(6):859-874.
39. Bentzinger C.F., et al. Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. Skelet Muscle 2013, 3(1):p6.
40. Cunningham J.T., et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007, 450(7170):736-740.
41. Romanino K., et al. Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function. Proc Natl Acad Sci U S A 2011, 108(51):20808-20813.
42. Goo C.K., et al. PTEN/Akt signaling controls mitochondrial respiratory capacity through 4E-BP1. PLoS ONE 2012, 7(9):pe45806.
43. Polak P., et al. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 2008, 8(5):399-410.
44. Liu M., et al. Grb10 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1. Cell Metab 2014, 19(6):967-980.
45. Hagiwara A., et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 2012, 15(5):725-738.
46. Yuan M., et al. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J Biol Chem 2012, 287(35):29579-29588.
47. Hung C.M., et al. Rictor/mTORC2 loss in the Myf5 lineage reprograms brown fat metabolism and protects mice against obesity and metabolic disease. Cell Rep 2014, 8(1):256-271.
48. Betz C., Hall M.N. Where is mTOR and what is it doing there?. J Cell Biol 2013, 203(4):563-574.
49. Sebastian D., et al. Mitofusin 2 (Mfn2) links mitochondrial endoplasmic reticulum function with insulin signaling is essential for normal glucose F homeostasis. Proc Natl Acad Sci US A 2012, 109(14):5523-5528.
50. Colombi M., et al. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction. Oncogene 2011, 30(13):1551-1565.
51. Duvel K., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010, 39(2):171-183.
52. Robitaille A.M., et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 2013, 339(6125):1320-1323.
53. Ben-Sahra I., et al. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013, 339(6125):1323-1328.
54. Rosen E.D., Spiegelman B.M. What we talk about when we talk about fat. Cell 2014, 156(1-2):20-44.
55. Cybulski N., et al. mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci U S A 2009, 106(24):9902-9907.
56. Kumar A., et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 2010, 59(6):1397-1406.
57. Cornu M., Albert V., Hall M.N. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 2013, 23(1):53-62.
58. Ricoult S.J., Manning B.D. The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep 2013, 14(3):242-251.
59. Lamming D.W., Sabatini D.M. A Central role for mTOR in lipid homeostasis. Cell Metab 2013, 18(4):465-469.
60. Kenerson H.L., Yeh M.M., Yeung R.S. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. PLoS ONE 2011, 6(3):pe18075.
61. Yecies J.L., et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 2011, 14(1):21-32.
62. Sengupta S., et al. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 2010, 468(7327):1100-1104.
63. Peterson T.R., et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146(3):408-420.
64. Umemura A., et al. Liver damage inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 2014, 20(1):133-144.
65. Cornu M., et al. Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21. Proc Natl Acad Sci U S A 2014, 111(32):11592-11599.
66. Bookout A.L., et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 2013, 19(9):1147-1152.
67. Csibi A., et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013, 153(4):840-854.
68. Choo A.Y., et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 2010, 38(4):487-499.
69. Newsholme P., et al. Glutamine and glutamate - their central role in cell metabolism and function. Cell Biochem Funct 2003, 21(1):1-9.
70. Fischer J.E., Chance W.T. Total parenteral nutrition, glutamine, and tumor growth. JPEN J Parenter Enteral Nutr 1990, 14(4 Suppl.):86S-89S.
71. Souba W.W. Glutamine and cancer. Ann Surg 1993, 218(6):715-728.
72. DeBerardinis R.J., et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7(1):11-20.
73. Lamming D.W., et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335(6076):1638-1643.
74. Lamming D.W., et al. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell 2014, 13(5):911-917.
75. Egan B., Zierath J.R. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 2013, 17(2):162-184.
76. Yang J. Enhanced skeletal muscle for effective glucose homeostasis. Prog Mol Biol Transl Sci 2014, 121:133-163.
77. Mackenzie R.W., Elliott B.T. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2014, 7:55-64.
78. Lai K.M., et al. Conditional activation of Akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004, 24(21):9295-9304.
79. Fraenkel M., et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008, 57(4):945-957.
80. Houde V.P., et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010, 59(6):1338-1348.
81. Johnston O., et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008, 19(7):1411-1418.
82. Castets P., et al. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab 2013, 17(5):731-744.
83. Kumar A., et al. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol 2008, 28(1):61-70.
84. Cone R.D., et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001, 25(Suppl. 5):S63-S67.
85. Arora S., Anubhuti Role of neuropeptides in appetite regulation and obesity - a review. Neuropeptides 2006, 40(6):375-401.
86. Neary N.M., Goldstone A.P., Bloom S.R. Appetite regulation: from the gut to the hypothalamus. Clin Endocrinol (Oxf) 2004, 60(2):153-160.
87. Yang S.B., et al. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 2012, 75(3):425-436.
88. Kocalis H.E., et al. Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis. Mol Metab 2014, 3(4):394-407.
89. Mori H., et al. Critical role for hypothalamic mTOR activity in energy balance. Cell Metab 2009, 9(4):362-374.
90. Matsuzaki H., et al. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A 2003, 100(20):11285-11290.
91. Iskandar K., et al. PDK-1/FoxO1 pathway in POMC neurons regulates Pomc expression and food intake. Am J Physiol Endocrinol Metab 2010, 298(4):E787-E798.